polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride
NULYTELY (polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride) by R-Pharm US is osmotic activity [moa]. First approved in 1991.
Drug data last refreshed 10h ago · AI intelligence enriched 13h ago
NULYTELY is an oral osmotic laxative solution containing polyethylene glycol 3350 and electrolytes used for bowel cleansing prior to colonoscopy or other GI procedures. It works by drawing water into the intestines through osmotic activity, promoting bowel evacuation without systemic absorption. This is a foundational preparation agent in gastroenterology with decades of clinical utility.
Product is in late-stage lifecycle with minimal Medicare spending; team size likely small and focused on defensive marketing and generic transition planning.
Osmotic Activity
Osmotic Laxative
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NULYTELY roles are concentrated in commercial defense and generic transition management rather than growth or innovation. This is a mature product suitable for professionals seeking stable, procedurally-focused work in a non-specialty GI market with limited upside.
Worked on NULYTELY at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo